192 related articles for article (PubMed ID: 1432936)
1. Legal and regulatory developments of the 1990s in oral care products: learning from what has come before.
O'Reilly JT
J Public Health Dent; 1992; 52(6):396-400. PubMed ID: 1432936
[TBL] [Abstract][Full Text] [Related]
2. FDA regulation of OTC oral health care drug products.
Rippere JL
J Public Health Dent; 1992; 52(6):329-32. PubMed ID: 1432917
[TBL] [Abstract][Full Text] [Related]
3. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
4. Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2016 Nov; 81(226):84465-77. PubMed ID: 27906534
[TBL] [Abstract][Full Text] [Related]
5. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
6. The FDA: is it protecting the public with one hand tied behind its back?
Shedlin RS
Law Med Health Care; 1992; 20(3):253-7. PubMed ID: 1434771
[No Abstract] [Full Text] [Related]
7. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
[TBL] [Abstract][Full Text] [Related]
8. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Feb; 67(27):5942-3. PubMed ID: 11837282
[TBL] [Abstract][Full Text] [Related]
9. How the FDA and the ADA affect development of prescription drugs for oral care.
Cooley WE
J Public Health Dent; 1992; 52(6):350-2. PubMed ID: 1432922
[TBL] [Abstract][Full Text] [Related]
10. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
11. The Surprising Reach of FDA Regulation of Cannabis, Even After Descheduling.
O'Connor SM; Lietzan E
Am Univ Law Rev; 2019; 68(3):823-925. PubMed ID: 30919712
[TBL] [Abstract][Full Text] [Related]
12. FDA: friend or foe?
Lewis TS
Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675
[TBL] [Abstract][Full Text] [Related]
13. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
[TBL] [Abstract][Full Text] [Related]
14. Regulatory watch: Innovative drug availability in China.
Shao L; Xu L; Li Q; Chakravarthy R; Yang Z; Kaitin KI
Nat Rev Drug Discov; 2016 Nov; 15(11):739-740. PubMed ID: 27765941
[No Abstract] [Full Text] [Related]
15. Implications of FDA's proposal to include foreign marketing experience in the over-the-counter drug review process.
Pinco RG
Food Drug Law J; 1998; 53(1):105-22. PubMed ID: 11795327
[No Abstract] [Full Text] [Related]
16. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
[TBL] [Abstract][Full Text] [Related]
17. Teaching non-FDA approved nonprescription products: Educating students about potential risks and liability.
Van Dusen V; Pray WS
Curr Pharm Teach Learn; 2019 Jul; 11(7):655-657. PubMed ID: 31227086
[TBL] [Abstract][Full Text] [Related]
18. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
19. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 May; 67(90):31125-7. PubMed ID: 12001972
[TBL] [Abstract][Full Text] [Related]
20. Regulation of oral chemotherapeutic products in the United States.
Trummel CL
J Dent Res; 1994 Mar; 73(3):704-8. PubMed ID: 8163741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
